Company Analysis
Sign in

Vir Biotechnology, Inc. (VIR)

Nasdaq: VIR · Biological Products, (No Diagnostic Substances) · San Francisco, CA · filing with the SEC since 2018
Full chart Alerts Compare
Grade5.2
◀ Past 7.1● Present 4.3▶ Future 4.5
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$68.6M-7.6%
Net income-$438M+16.1%
Earnings per share$-3.16+17.5%
Operating cash flow-$392M+12.2%
Cash$241M-24.4%
Debtn/a
Shareholders’ equity$765M-33.5%
Shares, diluted138.5M+1.7%
Return on equity-57.2%
The recordfrom its filings
Filings in 2026106
Newest filingNov 12 · 424B5
Annual reportFeb 23, 2026
Quarterly reportNov 4, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$2.9M
Insider buys, 12 months$0.00
Patents granted39
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $303MNet income -$185MCash from operations -$141Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form 424B5
Shelf offering
Open the filing on sec.gov
Nov 12, 2026 · SEC EDGAR · Form S-3ASR
Shelf registration
Open the filing on sec.gov
Nov 10, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Nov 9, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Nov 4, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 4, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Nov 4, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton VIR · research, not advice